



MSK Innovation Hub



Memorial Sloan Kettering
Cancer Center



Who We Are

As the world's oldest and largest private cancer center, Memorial Sloan Kettering Cancer Center (MSK) has devoted more than 135 years to exceptional patient care, influential educational programs, and innovative research to discover more effective strategies to prevent, control and, ultimately, cure cancer.

MSK is home to more than 20,000 physicians, scientists, nurses and staff united by a relentless dedication to conquering cancer.

Today, we are one of 51 National Cancer Institute-designated Comprehensive Cancer Centers, with state-of-the-art science and technology supporting groundbreaking clinical studies, personalized treatment, and compassionate care for our patients. We also train the next generation of clinical and scientific leaders in oncology through our continually evolving educational programs, here and around the world.

Year after year, we are ranked among the top two cancer hospitals in the country, consistently recognized for our expertise in adult and pediatric oncology specialties. www.mskcc.org.

www.mskcc.org

Learn more about the MSK Innovation Hub

The MSK Innovation Hub brings together health technology innovators and MSK's exceptional community of researchers, clinicians, and digital health professionals through a program designed to advance the prevention, treatment, and cure of cancer.

The MSK Innovation Hub is targeted at accelerating development of innovative products and businesses that will make a meaningful impact in the lives of people with cancer and caregivers.





What We Do (and Don't Do)

First, what we don't do: We are not providing direct funding through the MSK Innovation Hub program and generally not providing business guidance to industry participants. Because of this, we are complementary to investors and other business accelerators focused on those disciplines.

But here's what we DO do: The MSK Innovation Hub uniquely provides access to a real-world oncology research and clinical care environment, including all the physical, intellectual, and digital assets that this encompasses.

De-identified data is a component, but we also have deep expertise in clinical validation. We work extensively with the FDA. We have a unique patient population, exceptional facilities, and most of all, leading scientific innovators in numerous specialty fields. Bringing all of these strengths together, we may help design or deploy an application, train an algorithm, develop a new test, validate a biomarker, or discover a predictor.

What the candidate company does: What the company brings to the MSK Innovation Hub collaborative relationship is a fledgling product or idea and the appropriate business operations. Together, we advance the science and technology to a proven production solution, as we seek to advance the state of the art of oncology together.

Our Goals

Goal 1

Create opportunities to partner with world-class clinicians, scientists, and researchers to bring top expertise into product design, development, and validation.

Goal 2

Provide access to leverage MSK's digital assets, which include de-identified clinical and genomic data acquired through decades of patient care and research.

Goal 3


Forge network connections between influential leaders, subject matter experts, and investors in the digital healthcare and life sciences ecosystem.



Our History

In 2020, we selected our first MSK Innovation Hub cohort of collaborators. Our partners spanned different technology areas including digital therapeutics and AI/machine learning.

Now, teams across MSK are working with an expanding-number of companies through the MSK Innovation Hub. Together, we will help develop their technologies into impactful innovations — well positioned for commercialization and application in healthcare and medical research.



COMPANY OVERVIEW

Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to serving patients experiencing cancer. In September 2021, the company announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK) through the MSK Innovation Hub to help advance the development of Blue Note's prescription digital therapeutic (PDT) candidate to treat fear of cancer recurrence.

PROBLEMS WE'RE SOLVING

There are about 18 million cancer patients and survivors in the U.S. today. Nearly half of all cancer patients experience psychosocial distress, anxiety, or depression. All too many of these cancer patients and survivors are never referred to mental health specialists.

"Nearly all cancer patients face fear and uncertainty following their treatment, and for some, such fear can be distressing, preoccupying, and debilitating," said Wendy Lichtenthal, PhD, Attending Psychologist at MSK. "This can impact their mental and physical health, experience with medical care, and quality of life. We look forward to collaborating with Blue Note on this important project to help patients cope with their fears of recurrence."



WORKING WITH MSK

The collaborators will come together under MSK's Innovation Hub program. "We are excited for this opportunity to further our partnership with MSK," said Geoffrey Eich, CEO of Blue Note Therapeutics. "This new collaboration will give Blue Note access to leading cancer experts to advise and inform the development of our therapeutic, increasing our capacity to reach patients."





Work with us!

For companies: We're always on the lookout for innovators to work with! Please contact us at iHub@mskcc.org to get in touch and explore opportunities to work together.

For investors, including venture capitalists: As our program evolves and grows, we seek to connect with other members of the innovation ecosystem including investors, institutions, and other accelerator programs that have a focus on the digital health space. To get in touch with us and learn more about ways we may work together, please send a note to iHub@mskcc.org.

For more information about Digital Health opportunities at MSK, [visit us on the web.](#)